Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Hypochondroplasia Clinical Trial

Official title:
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated Over a Period of 3 Years or 5 Years if Applicable, in Comparison With a Historic Cohort of Non-treated Children With Hypochondroplasia

Status Completed

Clinical Trial Summary

This study is conducted to describe the efficacy and safety of recombinant human growth hormone (r-hGH) treatment Saizen® on children with hypochondroplasia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01111019
Study type	Interventional
Source	Merck KGaA, Darmstadt, Germany
Contact
Status	Completed
Phase	Phase 2
Start date	March 21, 2006
Completion date	January 17, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05328050` - Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Recruiting	`NCT06212947` - A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Recruiting	`NCT06410976` - Prospective Clinical Assessment Study in Children With Hypochondroplasia
Enrolling by invitation	`NCT06455059` - Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia	Phase 3
Completed	`NCT01541306` - C-Type Natriuretic Peptide and Achondroplasia	N/A